Home > White paper: A novel strategy for vaccine development and commercialization engine

White paper: A novel strategy for vaccine development and commercialization engine

mockup-white-paper-8

Despite the growing global burden of infectious diseases, the development of vaccines targeting endemic priority pathogens remains hindered by significant funding gaps and limited commercial incentives. While pandemic preparedness has attracted substantial investment, many bacterial pathogens continue to be overlooked, leaving promising vaccine candidates without a clear path to market.

Traditional biotech models often struggle to advance these candidates through clinical development and commercialization, particularly when expected returns on investment fall below conventional commercial benchmarks. Bridging this gap requires new approaches that align public health priorities with sustainable development and commercialization strategies.

First presented during Alcimed’s Healthcare Strategy Practice’s keynote presentation at Vaccine Congress Europe in October 2026, this white paper explores how lessons learned from antibiotic development, particularly the model of the Global Antibiotic Research and Development Partnership (GARDP), could be applied to endemic priority vaccine development. Building on this approach, the paper introduces the concept of an Endemic Pathogen Vaccines Engine (EPV Engine): a collaborative model designed to advance promising vaccine candidates through a network of external partners while retaining the strategic capabilities needed to drive development, regulatory approval, and commercialization. The EPV engine is built on the Healthcare Strategy Practice’s comprehensive view of the field and aims at presenting an engine that is realistic if currently hypotheical.

In this white paper, discover:

  • The key roadblocks to endemic vaccine development, from insufficient R&D funding and the mid-stage “valley of death” to the limitations of traditional biotech innovation.
  • The lessons learned from antibiotic development, and how GARDP’s partnership-driven model could be adapted to vaccine development.
  • A new approach to vaccine development and commercialization, leveraging existing clinical, regulatory and manufacturing capabilities through strategic partnerships.
  • The key success factors for building an EPV Engine, including vaccine asset selection, funding strategies, technology transfer, procurement and commercialization partnerships.

Download our white paper to explore how an alternative development model could help bridge the gap between public health needs and commercial viability, bringing promising endemic vaccine candidates closer to registration and commercialization.

More insights on the vaccine industry